048410.KQ Hyundai Bioscience Co., Ltd.
KOEHealthcareAs of 2026-08-18 07:58
Why 048410.KQ matters now
Hyundai Bioscience Co., Ltd. (048410.KQ) is a Korea stock in Healthcare. The latest InvestLog snapshot shows ₩7,560.00 with -5.97% on the session and ₩729.58B in market capitalization.
Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E -33.44, gross margin -11.3%, and operating margin -591.8%.
Valuation
P/E (TTM)
-33.44
PEG
—
P/B
6.49
P/S
232.85
EV/EBITDA
-59.78
DCF Value
—
FCF Yield
-2.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-11.3%
Operating Margin
-591.8%
Net Margin
-679.9%
ROE
-19.0%
ROA
-16.5%
ROIC
-14.5%
Listing Info
Market
Korea
Exchange
KOE
Currency
KRW
Sector
Healthcare
Industry
Biotechnology
Country
KR
Hyundai Bioscience Co., Ltd. is a biotechnology firm dedicated to creating and commercializing bio-fusion technologies that enable the precise delivery of active compounds throughout the human anatomy. The company offers Vitabrid C12, a novel vitamin C product engineered to provide active vitamin C directly to the skin. Additionally, it is advancing organic-inorganic hybrid technology, which functions as a sophisticated drug delivery system. This system integrates bio-friendly minerals to ensure the targeted and efficient transport of active substances to specific sites, a capability also leveraged in its anticancer drug carrier innovations. The enterprise was established in 2000 and is headquartered in Seoul, South Korea.